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Abstract: 
The knowledge captured in patent and scientific research literature 
stimulates new ideas and fosters new drug development efforts. 
Manufacturers and entrepreneurs dedicated to the sale of ‘research 
chemicals’ and/or new psychoactive substances (NPS) also make use of the 
access of information to identify, prepare and launch a range of new 
substances. One of the most recent compounds to appear on the NPS 
market was the phenmetrazine analog 3-fluorophenmetrazine (3-FPM) that 
represented one of many phenylmorpholines designed to explore treatment 
options in areas such as obesity and drug dependence. The anorectic drug 
analogs phenmetrazine and phendimetrazine, used as prescription 
medicines before they were withdrawn, feature amphetamine-like 
properties associated with monoamine release and available data on 3-FPM 
suggest that the effects might show mechanistic overlaps. This study 
describes the synthesis and extensive analytical characterization of 3-FPM 
and its differentiation from synthesized ortho- and para- substituted 
isomers, 2-FPM and 4-FPM. This study was triggered by the purchase of 
five powdered samples advertised as 3-FPM by five different Internet 
vendors based in the United Kingdom. The analytical data obtained for the 
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vendor samples were consistent with the synthesized 3-FPM standard and 
differentiation between all three isomers was possible. The presence of 
positional isomers and the absence of suitable reference material can cause 
difficulties in the day-to-day operation of forensic work and given the rate 
at which many of the newly emerging NPS appear on the market, a 
comprehensive approach is needed when attempting to decipher the 
identity of NPS arriving onto the drug market. 
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Abstract 
 
The knowledge captured in patent and scientific research literature stimulates 
new ideas and fosters new drug development efforts. Manufacturers and 
entrepreneurs dedicated to the sale of ‘research chemicals’ and/or new 
psychoactive substances (NPS) also make use of the access of information to 
identify, prepare and launch a range of new substances. One of the most 
recent compounds to appear on the NPS market was the phenmetrazine 
analog 3-fluorophenmetrazine (3-FPM) that represented one of many 
phenylmorpholines designed to explore treatment options in areas such as 
obesity and drug dependence. The anorectic drug analogs phenmetrazine 
and phendimetrazine, used as prescription medicines before they were 
withdrawn, feature amphetamine-like properties associated with monoamine 
release and available data on 3-FPM suggest that the effects might show 
mechanistic overlaps. This study describes the synthesis and extensive 
analytical characterization of 3-FPM and its differentiation from synthesized 
ortho- and para- substituted isomers, 2-FPM and 4-FPM, respectively. This 
study was triggered by the purchase of five powdered samples advertised as 
3-FPM by five different Internet vendors based in the United Kingdom. The 
analytical data obtained for the vendor samples were consistent with the 
synthesized 3-FPM standard and differentiation between all three isomers 
was possible. The presence of positional isomers and the absence of suitable 
reference material can cause difficulties in the day-to-day operation of 
forensic work and given the rate at which many of the newly emerging NPS 
appear on the market, a comprehensive approach is needed when attempting 
to decipher the identity of NPS arriving onto the drug market. 
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Introduction 
 
Over the past number of years in Europe, there has been an unprecedented 
increase in the number, types and seizures of chemicals frequently referred to 
as new psychoactive substances (NPS). There was no change to this trend in 
2014 as a total of 101 new substances was detected and reported for the first 
time by the European Union Early Warning System, which brings the total 
number of substances being monitored by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) to more than 450 substances.[1] The 
nature of substances available for purchase is not limited to compounds 
derived from illicit drugs as increasing ranges of compounds derived from 
medicinal products have also joined the catalogs of NPS suppliers.[2] 
 
Phenmetrazine (3-methyl-2-phenylmorpholine) is a synthetic morpholine 
derivative of amphetamine that includes a phenylisopropylamine skeleton 
where the terminal amine is incorporated into a morpholine ring.[3] In the 
1950s, phenmetrazine and its N-methyl derivative phendimetrazine (3,4-
dimethyl-2-phenylmorpholine) (Figure 1A) were developed within the 
pharmaceutical setting as sympathomimetic weight-control medications 
considered to show less abuse liability compared to other amphetamine 
anorexiants.[3-6] Phenmetrazine is a potent substrate for norepinephrine and 
dopamine transporters and displays stimulant properties similar to those of 
amphetamine, whereas phendimetrazine is classified as a pro-drug and 
exerts its pharmacological effect through biotransformation to 
phenmetrazine.[3, 7-8] Following the observation of adverse drug reactions 
relating to phenmetrazine use, it was withdrawn from the market and 
classified as a Schedule II drug under the United Nations Convention on 
Psychotropic Substances 1971. Similarly, phendimetrazine was listed in 
Schedule IV of the Convention.[9-10] In the 1970s, ph nmetrazine (street name 
‘Prellies’) reportedly replaced amphetamine after it became known in popular 
culture due to its association with The Beatles.[11-13] 
 
Recent studies indicate that phendimetrazine may be a suitable candidate for 
the treatment of cocaine addiction.[14-19] Phendimetrazine has also been 
suggested as an effective and safer alternative to d-amphetamine as it may 
simultaneously function as a monoamine uptake inhibitor (via the parent drug) 
and as a monoamine releaser (via the active metabolite).[14] However in 
recent years, it has also been observed that NPS manufacturers are also 
finding new uses for established (and/or withdrawn) medicines since several 
derivatives of these medicinal products can be found as ‘research chemicals’ 
on the NPS market.  
 
Similar to that of other anorectic agents such as aminorex,[20,21] the chemical 
structure of phenmetrazine may be open to structural manipulation through 
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substitution of the phenyl and/or morpholine ring. In 2011, a study by Blough 
et al. featured the synthesis and pharmacological evaluation of many 
phenylmorpholine analogs for potential therapeutic applications.[3] For 
example, 2-(3-fluorophenyl)-3-methylmorpholine (3-fluorophenmetrazine, 3-
FPM, PAL-593) and 2-(4-fluorophenyl)-3-methylmorpholine (4-
fluorophenmetrazine, 4-FPM, PAL-748) (Figure 1A) were synthesized and 
pharmacological evaluations revealed that both isomers were substrate-type 
monoamine releasers with higher selectivity toward catecholamines.[3] In the 
synaptosomal preparations used, 3-FPM showed higher potency than 4-FPM 
in the ability to induce dopamine and norepinephrine release and further 
investigations related to the 2-FPM isomer are needed for further 
comparisons.[3] Studies such as these can be exploited by manufacturers of 
NPS who are examining the scientific and patent literature for compounds that 
are considered potentially suitable as NPS products. In the United Kingdom, 
one of the psychostimulants available for purchase, either individually or as a 
component in a mixture present in range of branded products, was N-methyl-
1-(thiophen-2-yl)propan-2-amine (methiopropamine, MPA). A recent change 
in legislation placed this substance under control[22]  which makes it possible 
that 3-FPM might act as a replacement in such products.   
   
This study reports on the first phenmetrazine analog to be encountered on the 
NPS drug market, namely 3-fluorophenmetrazine (3-FPM). The study 
describes the synthesis and analytical characterization of 3-FPM and 
differentiation from its ortho- and para- substituted isomers, 2-FPM and 4-
FPM, respectively, that have also been prepared for comparison (Figure 1A). 
This was triggered by the purchase of five powdered samples advertised as 3-
FPM by five different Internet vendors based in the United Kingdom. Various 
chromatographic, spectroscopic and mass spectrometric platforms were 
employed followed by structural investigations using X-ray crystal structure 
analysis. 
 
 
Reagents and standards 
 
All reagents and dry solvents used in the syntheses were obtained from 
Sigma Aldrich Ltd (Arklow, Co. Wicklow, Ireland). 2-, 3- and 4-
fluoroproiophenone were obtained from Alfa Aesar (Heysham, United 
Kingdom). Preparative silica gel thin layer chromatography plates (UV254, GF 
20 x 20 cm, 2000 microns) were obtained from Analtech (Newark, United 
States). LC-MS grade solvents were obtained from Fisher Scientific (Dublin, 
Ireland). Five samples, advertised as 3-fluorophenmetrazine (3-FPM), were 
purchased from five different online vendors based in the United Kingdom.  
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Syntheses 
 
2-(2-Fluorophenyl)-3-methylmorpholine (2-fluorophenmetrazine, 2-FPM) 
 
A solution of bromine (0.05 mol, 4.34 g, 1.40 mL) in dichloromethane (26.5 
mL) was added slowly to a solution of 2-fluoropropiophenone (26.3 mmol, 4.0 
g) in dichloromethane (26.5 mL). The mixture was stirred for 1 h, dried 
(anhydrous magnesium sulfate) and the solvent was removed to afford a 
colorless oil (21.6 mmol, 5.0 g). This oil was dissolved in acetonitrile (66.25 
mL) and the addition of ethanolamine followed (0.055 mol, 3.33 g, 3.30 mL). 
The reaction mixture was heated for 3 h at 40 oC and then left to stir overnight 
at room temperature. To this mixture, a solution of sodium borohydride (0.1 
mol, 4.0 g) in water (100 mL) was added and allowed to stir at room 
temperature overnight. The reaction mixture was partitioned between 
dichloromethane and water, the organic layer collected, dried (anhydrous 
magnesium sulfate), and the solvent removed to give a bright-yellow, viscous 
oil (15.3 mmol, 3.257g). This oil was then purified by flash chromatography 
(ethanol:ethyl acetate, 6:4) to afford a yellow oil (3.5 mmol, 0.739 g, 23%). 
The oil was dissolved in dichloromethane (5 mL) and conc. sulfuric acid (0.41 
mol, 40.48 g, 22 mL) was added to the mixture (reaction vessels kept on ice) 
and allowed to stir overnight. Water (250 mL) was added and the reaction 
mixture was made alkaline with 10 M sodium hydroxide and extracted into 
dichloromethane. Drying with magnesium sulfate and removal of solvent 
yielded crude 2-fluorophenmetrazine (3.1 mmol, 0.608 g) as a cloudy, yellow 
oil. Purification was conducted by preparative thin layer chromatography using 
dichloromethane/methanol (8:2) as the mobile phase. The purified band was 
removed from the TLC plate, dissolved in ethanol, centrifuged and isolated as 
a white solid (1.20 mmol, 0.233 g, 5%).  
 
Preparation of 2-fluorophenmetrazine fumarate  
 
To the purified sample, dissolved in 0.5 mL methanol, was added fumaric acid 
(1.20 mmol, 0.139 g) dissolved in 2 mL methanol. The solvent was removed 
and the addition of tert.-butyl methyl ether (TBME) afforded a white solid 
powder (1.0 mmol, 0.332 g): m.p. 150 oC (148–152 oC). 1H NMR (DMSO) δ 
ppm 7.48 (t; J = 7.4 Hz; 1H; Ar-CH; H-2’), 7.42–7.35 (m; 1H; Ar-CH; H-4’), 
7.27–7.17 (m; 2H; Ar-CH; H-1 and H-3’), 6.55 (s; 2H; CH; fumarate), 4.50–
4.46 (m; 1H; CH; H-2), 3.97–3.68 (m; 2H; CH2; H-6), 3.06–3.02 (m; 3H; 1 x 
CH, 1 x CH2; H-3, H-5), 0.85 (d; J = 6.4 Hz; 3H; CH3). 13C NMR (DMSO) δ 
ppm 167.0526 (C=O; fumarate), 159.51 (JCF = 243.6 Hz; Ar-CF; C-6’), 134.60 
(CH; fumarate), 130.49 (JCF = 8.2 Hz; Ar-CH; C-2’), 128.86 (JCF = 3.5 Hz; Ar-
CH; C-3’), 125.88 (JCF = 11.5 Hz; Ar-CH; C-5’), 124.73 (JCF = 3.3 Hz; Ar-CH, 
C-4’), 115.12 (JCF = 22.1 Hz; Ar-CH; C-1), 75.85 (CH; C-2), 65.63 (CH2; C-6), 
54.54 (CH; C-3), 44.10 (CH2; C-5), 15.60 (CH3); 19F NMR (d6-DMSO) δ ppm –
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118.64; HR-ESIMS observed m/z 196.1143 (theory [M + H]+: C11H15FNO+ m/z 
196.1132 (∆ = 1.25 ppm). 
 
 
2-(3-Fluorophenyl)-3-methylmorpholine (3-fluorophenmetrazine, 3-FPM) 
 
The reaction was carried out as described above using 3-fluoropropiophenone 
instead yielding 3-fluorophenmetrazine free base as a colorless oil (0.5 mmol, 
0.093 g, 2%). The free base was converted to the fumarate salt yielding a 
white solid (0.5 mmol, 0.128 g): m.p.178 oC (176–180 oC). 1H NMR (DMSO) δ 
ppm 7.43–7.36 (m; 1H; Ar-CH; H-3’), 7.21–7.12 (m; 3H; Ar-CH; H-2’, H-4’, H-
6’), 6.55 (s; 2H; CH; fumarate), 4.13 (d; J = 6.0 Hz; 1H; CH; H-2), 3.94–3.62 
(m; 2H; CH2; H-6), 3.05–2.95 (m; 2H; CH2; H-5), 2.93–2.86 (m; 1H; CH; H-3), 
0.80 (d; J = 6.5 Hz; 3H; CH3); 13C NMR (DMSO) δ ppm 167.29 (C=O, 
fumarate), 161.94 (JCF = 241.9 Hz; Ar-CF; C-1), 142.23 (JCF = 6.5 Hz; Ar-CH; 
C-5’), 134.72 (CH; fumarate), 130.10 (JCF = 8.4 Hz; Ar-CH; C-3’), 123.68 (JCF 
= 1.2 Hz; Ar-CH; C-4’), 114.86 (JCF = 20.8 Hz; Ar-CH; C-2’), 114.11 (JCF = 21.7 
Hz; Ar-CH; C-6’), 82.76 (CH; C-2), 65.76 (CH2; C-6), 54.89 (CH; C-3), 44.44 
(CH2; C-5), 16.40 (CH3); 19F NMR (d6-DMSO) δ ppm –113.73; HR-ESIMS 
observed m/z 196.1138 (theory [M + H]+: C11H15FNO+ m/z 196.1132 (∆ = 3.12 
ppm).  
 
2-(4-Fluorophenyl)-3-methylmorpholine (4-fluorophenmetrazine, 4-FPM) 
 
The reaction was carried out as described above using 4-fluoropropiophenone 
instead yielding the 4-fluorophenmetrazine free base as a white solid (0.8 
mmol, 0.162 g, 3%). The free base was converted to the fumarate salt 
yielding a white solid powder (0.8 mmol, 0.240 g): m.p.170–172 oC.1H NMR 
(DMSO) δ ppm 7.43–7.34 (m; 2H; Ar-CH; H-4’, H-6’), 7.22–7.11 (m; 2H; Ar-
CH; H-1, H-3’), 6.55 (s; 2H; CH; fumarate), 4.19 (d; J = 9.4 Hz; 1H; CH; H-2), 
3.96–3.67 (m; 2H; CH2; H-6), 3.10–2.96 (m; 3H; 1 x CH, 1 x CH2; H-3; H-5), 
0.82 (d; J = 6.6 Hz; 3H; CH3). 13C NMR (DMSO) δ ppm 167.13 (C=O; 
fumarate), 161.83 (JCF = 242.3 Hz; Ar-CF; C-2’), 135.11 (JCF = 2.8 Hz; Ar-CH, 
C-5’), 134.63 (CH; fumarate), 129.56 (JCF = 8.1 Hz; Ar-CH; C-6’), 129.51 (JCF 
= 8.1 Hz; Ar-CH; C-4’), 115.11 (JCF = 21.2 Hz; Ar-CH; C-1), 114.97 (JCF = 21.2 
Hz; Ar-CH; C-3’), 82.04 (CH; C-2), 65.21 (CH2; C-6), 54.67 (CH; C-3), 43.96 
(CH2; C-5), 15.81 (CH3); 19F NMR (d6-DMSO) δ –114.28 ppm; HR-ESIMS 
observed m/z 196.1134 (theory [M + H]+: C11H15FNO+ m/z 196.1132 (∆ = 0.86 
ppm). 
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Instrumentation 
 
Gas chromatography mass spectrometry  
 
The gas chromatography system consisted of an Agilent 6980 GC coupled to 
an Agilent 5973 MSD (Agilent, Little island, Cork) equipped with a HP-5ms 
column (30 m x 0.25 mm x 0.25 µm). The helium carrier gas flow rate was set 
at a constant flow of 1 mL/min in splitless mode. Injection port and transfer 
line temperatures were set at 250 oC and 280 oC. Oven temperature: 40 oC 
held for 1 min, ramped at 10 oC/min to 250 oC, within 22 minutes, then 
ramped again at 20 oC/min to 300 oC and held for 3 min. The total run time 
was 27.5 min.  
 
 
Liquid chromatography electrospray mass spectrometry 
 
LC-MS analyses were performed on an Agilent 1100 HPLC system equipped 
with a G13795 degasser, G1312A BinPump, a G1313A ALS and G1316A 
column oven (COLCOM) (Agilent, Little Island, Cork). Separation was 
obtained on a Kinetex phenyl-hexyl column (2.6 µm, 100 x 2.10 mm) 
Phenomenex (Cheshire, United Kingdom). The analytes were eluted under 
isocratic conditions using a mobile phase of 97% water and 3% acetonitrile 
(both containing 0.1% formic acid). The Agilent LC-MSD settings were as 
follows: positive electrospray mode, capillary voltage 3500 V, drying gas (N2) 
12 L/min at 350 oC, nebulizer gas (N2) pressure 50 psi, SIM m/z 196, 
fragmentor voltage 50 V. Samples for LC-MS analysis were dissolved in 
acetonitrile/water (1:1, containing 0.1% formic acid) at a concentration of 10 
µg/mL. The injection volume was 0.5 µL, flow rate was 0.4 mL/min and the 
column temperature was 30 oC. Total run time was 25 min. 
 
 
High-resolution electrospray mass spectrometry 
 
HR-ESI mass spectra were recorded by direct injection into a LTQ Orbitrap 
Discovery (Thermo Fisher Scientific, Bremen, Germany). Samples were 
dissolved in acetonitrile/water (1:1, containing 0.1% formic acid) and infused 
at a rate of 5 µL/min. Full accurate high-resolution (30000) mass scans were 
performed in positive electrospray mode. Measured accurate masses were 
within ± 5 ppm of the theoretical masses. The following conditions were used: 
drying gas (N2) 10 L/min, capillary temperature 310 oC, spray voltage 4 V, 
capillary voltage 22 V and tube lens 77 V. The mass calibration procedure 
was performed in both positive and negative mode using solutions of caffeine, 
L-methionyl-arginyl-phenylalanyl-alanine acetate × H20 (MRFA), Ultramark 
1621®, sodium docecyl sulfate and sodium taurocholate. 
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Thin layer chromatography 
 
Separations were conducted using TLC silica gel 60 (F254, 20 x 20 cm) 
aluminium sheets (Merck, Germany). The mobile phase used was ethyl 
acetate/methanol (8:2) with 0.1% ammonia (7N in methanol). All standards 
and vendor samples were dissolved in the mobile phase and vortex mixed 
before spotting onto the TLC plate. UV light at 254 nm was used for detection. 
 
Nuclear magnetic resonance spectroscopy 
 
All analytes were prepared in deuterated dimethyl sulfoxide (DMSO-d6) at a 
concentration of 20 mg/mL. 1H (600 MHz) and 13C (150 MHz) spectra were 
recorded on a Bruker AV600 NMR spectrometer using a 5 mm TCI cryoprobe. 
1H NMR spectra were referenced to an external TMS reference at δ = 0 ppm. 
19F (376 MHz) spectra were recorded on a Bruker DPX400 NMR 
spectrometer and the external reference was trifluorotoluene set at δ = -64 
ppm.  
 
 
X-ray crystallography 
Data were obtained for the synthesized 3-FPM standard and one 
representative vendor sample on a Bruker APEX DUO with Cu Kα and Mo Kα 
radiation (λ = 1.54178 and 0.71073 Å) using a MiTeGen micromount and at 
100(2) K (Oxford Cobra Cryosystem). The Bruker APEX2 software[23] was 
used to collect and reduce data, determine the space group, solve and refine 
the structure. Absorption corrections were applied using SADABS.[24] All final 
refinements were performed with SHELXL.[25] All non-hydrogen atoms were 
refined anisotropically. Hydrogen atoms were assigned to calculated positions 
using a riding model. Donor hydrogen atoms were refined for the 3-FPM 
standard and refined with restraints for the 3-FPM vendor sample. CCDC 
1418406 and 1418407 contains the supplementary crystallographic data for 
this investigation. Crystal data and structure refinement parameters were as 
follows:  
Synthesized 3-FPM standard: C13H16FNO3, M = 253.27, T = 100(2) K, 
Monoclinic, P21/c, a = 18.7821(8), 7.7948(3), c = 8.7467(4) Å, β = 
91.8726(14)°, V = 1279.86(9) Å3, Z = 4, µ (Cu Kα) = 0.863 mm−1, ρ = 1.314 
Mg/cm3, 14670 reflections collected, 2421 independent (Rint = 0.0367), aR1 = 
0.0516, wR2 = 0.1338 (I > 2σ(I)), S = 1.081. CCDC 1418406. 
 
Representative 3-FPM vendor sample: C11H15ClFNO, M = 231.69, T = 100(2) 
K, Monoclinic, Cc, a =6.1009(4), b = 29.1650(18), c = 7.0747(5) Å, β = 
111.322(2)°, V = 1172.66(14) Å3, Z = 4, µ (Mo Kα) = 0.313 mm−1, ρ = 1.312 
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Mg/cm3, 15349 reflections collected, 2125 independent (Rint = 0.0568), aR1 = 
0.0339, wR2 = 0.0653 (I > 2σ(I)), S = 1.028. CCDC 1418407. aR1 = Σ||Fo| − 
|Fc||/Σ|Fo|, wR2 = [Σw(Fo2 − Fc2)2/Σw(Fo2)2]1/2.   
 
Results and discussion 
 
Five powdered samples, advertised as 3-fluorophenmetrazine (3-FPM), were 
obtained from different online vendors in the United Kingdom and subjected to 
extensive analytical characterizations. The vendor samples were 
characterized as 3-FPM and consistent with the information given on the 
product labels which was verified by organic synthesis of this material. Given 
the challenges associated with the ability to correctly identify a suspected 
positional isomer, further investigations were carried out by syntheses and 
characterizations of the 2-, 3- and 4-fluorophenmetrazine isomers (2-, 3- and 
4-FPM). Currently, extensive analytical data on 3-FPM and its positional 
isomers appear to be lacking in the reported literature.  
 
The synthesis employed for the preparations of 2-, 3- and 4-FPM was 
adapted from Blough et al. (Figure 1B).[3] The synthesis involved bromination 
of the fluoropropiophenone starting material (a), yielding α-bromo-
fluoropropiophenone (b). This was reacted with ethanolamine to give the 
intermediate 1-(3-fluorophenyl)-2-((2-hydroxyethyl)amino)propan-1-one (c). 
Reduction to the alcohol (d) was achieved by reaction with sodium 
borohydride followed by reaction with concentrated sulfuric acid to aid 
cyclization and formation of the morpholine ring (e). It was found most 
practical to generate the fumarate salts to induce crystallization. The 
formation of hydrochloride salts was attempted for each FPM isomer, however 
sufficient yields were not obtained for analytical characterization. 
 
Similar to the aminorex analogs previously detected on the NPS market,[20,21] 
the fluorinated analogs of phenmetrazine contain two chiral centres which 
yield the potential for four stereoisomers and two racemic mixtures (i.e., cis- 
and trans-racemates) (Figure 1C). The results observed for the preparation of 
the FPM isomers were consistent with the reported synthesis of 
phenmetrazine where the formation of the more trans- isomer was 
reported.[26,27] Analytical characterization of the 3-FPM reference standard 
and vendor sample using X-ray crystallography concluded that both were 
consistent with the trans- isomeric form. The analyses of the five 3-FPM 
products also revealed high purity as judged by chromatographic 
characterizations and nuclear magnetic resonance spectroscopy (NMR) 
(supplemental data).     
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[Insert Figure 1 here] 
 
 
Analytical features 
 
Gas chromatography mass spectrometry (GC-MS) 
 
Initial analysis of the underivatized isomers by GC-MS failed to obtain 
separation between meta- and para- substituted 3- and 4-FPM isomers 
although separation for 2-FPM was feasible (Figure 2A). Derivatization with 
heptafluorobutric anhydride (HFBA) (Figure 2C) and pentafluoropropionic 
anhydride (PFBA) (Figure 2E) improved the chromatography results 
dramatically whereas reaction with trifluoroacetic anhydride (TFAA) (Figure 
3A – 3C) retained some overlap between 3-FPM and 4-FPM. The electron 
ionization (EI) mass spectra recorded for underivatized 3-FPM, and its HFBA 
and PFBA derivatives are shown in Figures 2B, 2D and 2F, respectively. A 
comparison of mass spectral data acquired for all three isomers were identical 
(supplemental information). A proposed fragmentation pathway for 
underivatized 3-FPM under EI-MS conditions is shown in Figure 3D. 
 
As mentioned above, derivatization of FPM isomers with TFAA gave 
incomplete separation but diagnostically useful information was obtained 
based on their mass spectra. The spectra obtained for FPM-TFAA isomers 
provided distinctive differences that facilitated differentiation of the 3-FPM 
isomer from its 2- and 4-FPM counterparts (Figure 3A – 3C). In addition to the 
molecular ion at m/z 291 that was detectable in all three mass spectra, an ion 
at m/z 290 was observed in the spectrum of 3-FPM-TFAA that was not 
detected in the other two instances. The detection of this ion was rationalized 
by a possible rearrangement that might have involved the loss of a hydrogen 
radical and the formation of a thermodynamically stable five membered ring. 
In this case, a bond would have been formed between the carbon at the 
ortho- position of the phenyl ring and the methyl group on the morpholine ring 
(Figure 3E). The proposed fragmentation pattern for the FPM-TFAA isomers 
is outlined in Figure 3E. The fragment observed at m/z 222 might have been 
the result of radical loss of CF3 via cleavage of the nitrogen in the morpholine 
ring. A further loss of carbon monoxide would be consistent with m/z 194. 
These fragment arrangements are similar to that obtained for TFAA 
derivatives of amphetamine-based designer drugs discussed in the 
literature.[28] Two dominant fragments were noticed at m/z 70 and m/z 167. 
The m/z 70 indicated a potential loss of the ring-substituted fluorobenzyl 
alcohol, which is suggested to give rise to a 2-methylazetidine ion (C4H8N+). 
The base peak at m/z 167 could have been accounted for by a loss of 
hydrogen cyanide from the m/z 194 ion, thus, resulting in a fragment with a 
formula of C10H12FO+, possibly consistent with ring-substituted (1-
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methoxypropyl)benzene ion. Further cleavage of a methyl radical could then 
result in the detection of a methyloxirane species at m/z 152. The loss of a 
hydroxyl group then leads to the formation of a cyclopropylium species at m/z 
135. The GC-MS analysis of vendor samples confirmed that all five test 
purchases were consistent with the identity of the 3-FPM isomer as claimed 
on the product label (supplemental information). 
 
[Insert Figures 2 and 3 here] 
 
 
Liquid chromatography mass spectrometry (HPLC-MS) 
 
Separation of all three fluorophenmetrazine isomers was deemed satisfactory 
with retention times of 16.18 min, 18.48 min and 19.34 min for 2-FPM, 4-FPM 
and 3-FPM, respectively (Figure 4A) and analysis of all five purchased 3-FPM 
samples revealed identical retention times. During initial method development, 
the reproducibility of retention times was found to be challenging but improved 
when exploring a mobile phase composition of 97% water and 3% acetonitrile 
(both containing 0.1% formic acid). 
 
The product ion spectra obtained from in-source collision-induced dissociation 
(CID) at increased fragmentor voltage (150 V) and the suggested dissociation 
pathways are shown in Figure 4B and 4C. The formation of m/z 178 might 
have represented a loss of methanol from the protonated molecule (m/z 196), 
consistent with C11H13FN+. The m/z 152 ion was consistent with a loss of 
ethylene oxide from [M + H]+ to form an aziridine species. The product ion at 
m/z 135 might have formed following the loss of ethenamine (C2H5N) from 
m/z 178 and/or the loss of NH3 from the aziridine species at m/z 152. A loss of 
HF from the m/z 135 ion might have resulted in the detection of m/z 115. 
Implementation of high-resolution mass spectrometry provided elemental 
compositions with acceptable mass accuracies consistent with the proposed 
structures (Figure 4C).  
 
 
[Insert Figure 4 here] 
 
Thin layer chromatography (TLC) 
 
It was encouraging to observe that TLC analysis also facilitated a successful 
separation of the three isomers as evidenced by distinct retardation factors of 
0.65, 0.51 and 0.43 for 2-, 3- and 4-FPM, respectively (Figure 5). This served 
as a valuable reminder that a seemingly basic separation technique should 
not be discounted when facing the challenge of dealing with the presence of 
isomers, particularly when operating within a forensic context where time and 
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financial constraints can be significant. Indeed, previous investigations on 
three methoxydiphenidine isomers (2-, 3-, and 4-MXP) have shown how 
useful TLC can be for the differentiation of NPS isomers.[29] 
 
[Insert Figure 5 here]  
 
 
 
X-ray crystallography  
 
Consistent with reports on phenmetrazine encountered in the literature,[26,27] it 
was observed that the adopted synthetic pathway used for the 
fluorophenmetrazine isomers led to the formation of the more stable trans-
racemate. X-ray crystal structure analysis was employed to investigate the 
structural features of the synthesized 3-FPM reference standard, in addition to 
one representative 3-FPM vendor sample (Figure 6). The 3-FPM reference 
standard was prepared as the fumarate salt, crystallized from ethyl 
acetate:methanol, and found to crystallize in the centrosymmetric space group 
P2(1)/c where one half of the fumarate was generated by symmetry 
(supplemental information). The crystal structure of the 3-FPM vendor sample 
is shown in Figure 6, and confirmed that it was manufactured as the 
hydrochloride salt, which crystallized in the polar space group Cc as the (S)-
enantiomer, i.e. showing (S)-conformation at C7 and C8. In both structures, 
the 3-FPM cation displayed the chair conformation consistent with earlier 
reports on phenmetrazine hydrochloride[30] and 3,5-dimethyl-2-(3-
chlorophenyl)-2-morpholinol hydrochloride, respectively.[31,32] An overlay of 
both 3-FPM phenmetrazinium cations shows that there was negligible impact 
on conformation when changing the counter ion with a weighted RMS 
deviation of 0.09 Å (F1–C14 of both moieties used, see supplemental 
information). The hydrogen bonding network in the 3-FPM vendor sample was 
similar to that in phenmetrazine hydrochloride with NH2+ÉCl- hydrogen bonds 
of ca. 3.06 and 3.08 Å forming a ion pair dimer array parallel to the a-axis. In 
the synthesized 3-FPM reference standard hydrogen bonding network was 
more complex. The fumarate ion contained more H-bonding acceptors and 
formed a 3D network and a much stronger association in comparison to the 
Cl- salt with hydrogen bonds ~2.69 Å between the morpholinium NH2+ÉO of 
the fumarate anion.  
 
[Insert Figure 6]  
 
A key challenge encountered in the development of new medicines that target 
monoamine transporters is the potential for abuse liability, which triggered an 
interest in the exploration of dual dopamine/serotonin releasers with low 
abuse potential.[33-36] At the same time, the knowledge generated by these 
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important research endeavors have also opened the door to unregulated and 
globalized markets that provide access to the general public, for example in 
the form of ‘research chemicals’ and NPS.[2] It is hoped that the increasing 
challenges associated with these developments do not interfere with the 
capacity of developing potentially promising medicines.  
 
Conclusion 
 
The release of new psychoactive substances onto the recreational drug 
market continues to create challenges for scientists in the forensic, clinical 
and toxicology fields. The appearance of substances such as 3-
fluorophenmetrazine reflects the gathering of information from the patent 
literature concerned with the development of potential medicines. A corollary 
of this approach is that the appearance of positional isomers has to be 
considered when facing the correct identification of substances considered as 
new psychoactive substances (NPS). The combination of test purchases, 
analytical characterization and confirmation by organic synthesis was found to 
be a useful and proactive approach for the generation of analytical data that 
may be of interest to a range of stakeholders. Given the rate at which many of 
newly emerging NPS appear on the market, increasing collaborations are 
needed between forensic science laboratories and academic institutions when 
attempting to actively engage in the challenges linked to the NPS 
phenomenon. 
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Figure captions: 
 
Figure 1. A. Chemical structures of phenmetrazine, its N-methyl derivative 
phendimetrazine and the fluorophenmetrazine (FPM) positional isomers. B. 
The synthesis pathway employed for the preparation of 2-, 3- and 4-FPM 
isomers. C. Structural representation of all four FPM enantiomers. 
 
Figure 2. Gas chromatographic (GC) separation achieved for the 
underivatized FPM isomers (A), the HFBA-FPM derivatives (C) and the 
PFBA-FPM derivatives (E). The electron ionization (EI) mass spectra 
recorded for underivatized 3-FPM, and its HFBA and PFBA derivatives are 
shown in Figure 2B, 2D and 2F, respectively. 
 
Figure 3. A-C. GC-MS data obtained for the FPM-TFAA isomers. D. A 
proposed fragmentation pathway for underivatized 3-FPM under EI-MS 
conditions. E. A proposed fragmentation pattern for the FPM-TFAA isomers 
under EI-MS conditions. 
 
Figure 4. A. HPLC separation achieved for all three fluorophenmetrazine 
isomers. B-C. The product ion spectra obtained from in-source collision-
induced dissociation (CID) at increased fragmentor voltage (150 V) and the 
suggested dissociation pathways with HR-MS providing elemental 
compositions with acceptable mass accuracies consistent with the proposed 
structures. 
 
Figure 5. TLC separation of the three isomers provided retardation factors of 
0.65, 0.51 and 0.43 for 2-, 3- and 4-FPM, respectively. 
 
Figure 6. Molecular structure achieved for 3-FPM vendor sample using x-ray 
crystal structure analysis. 
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Figure 1. A. Chemical structures of phenmetrazine, its N-methyl derivative phendimetrazine and the 
fluorophenmetrazine (FPM) positional isomers. B. The synthesis pathway employed for the preparation of 2-, 
3- and 4-FPM isomers. C. Structural representation of all four FPM enantiomers.  
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Figure 2. Gas chromatographic (GC) separation achieved for the underivatized FPM isomers (A), the HFBA-
FPM derivatives (C) and the PFBA-FPM derivatives (E). The electron ionization (EI) mass spectra recorded 
for underivatized 3-FPM, and its HFBA and PFBA derivatives are shown in Figure 2B, 2D and 2F, respectively. 
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Figure 3. A-C. GC-MS data obtained for the FPM-TFAA isomers. D. A proposed fragmentation pathway for 
underivatized 3-FPM under EI-MS conditions. E. A proposed fragmentation pattern for the FPM-TFAA isomers 
under EI-MS conditions.  
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Figure 4. A. HPLC separation achieved for all three fluorophenmetrazine isomers. B-C. The product ion 
spectra obtained from in-source collision-induced dissociation (CID) at increased fragmentor voltage (150 V) 
and the suggested dissociation pathways with HR-MS providing elemental compositions with acceptable 
mass accuracies consistent with the proposed structures.  
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Figure 5. TLC separation of the three isomers provided retardation factors of 0.65, 0.51 and 0.43 for 2-, 3- 
and 4-FPM, respectively.  
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Figure 6. Molecular structure achieved for 3-FPM vendor sample using x-ray crystal structure analysis.  
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